The enhancement of morphine antinociception in mice by Δ9- tetrahydrocannabinol

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 2, 1998, Pages 559-566

  Smith, Forrest L ^a   Cichewicz, Diana ^a   Martin, Zachary L ^a   Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoids; Morphine antinociception; Radiant heat nociception

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CP 55; DRONABINOL; MORPHINE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; DRUG SYNERGISM; HALLUCINOGENS; MALE; MICE; MICE, INBRED ICR; MORPHINE; PAIN MEASUREMENT; REACTION TIME; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL;

EID: 0032100491     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00012-4     Document Type: Article

References (47)

1. Beal J.E., Olson R., Laubenstein L., Morales J.O., Bellman P., Yangco B., Lefkowitz L., Plasse T.F., Shepard K.V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 10:1995;89-97.
2. Bloom A.S., Dewey W.L., Harris L.S., Brosius K.K. 9-nor-9β-Hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity. Comparisons with morphine J. Pharmacol. Exp. Ther. 200:1977;263-270.
3. 9-tetrahydrocannabinol in the rat and mouse. Phychopharmacologia. 25:1972;275-280.
4. Clark W.C., Janal M., Zeidenberg P., Nahas G.G. Effect of moderate and high doses of marihuana on thermal pain. A sensory decision theory analysis J. Clin. Pharmacol. 21:1981;299S-310S.
5. 9-tetrahydrocannabinol-induced responses and apparent agonist activity J. Pharmacol. Exp. Ther. 277:1996;586-594.
6. Compton D.R., Rice K.C., Costa B.R.D., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure activity relationship. Correlation of receptor binding and in vivo activities J. Pharmacol. Exp. Ther. 265:1993;218-226.
7. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 7:1941;274-279.
8. Devane W.A., Dysarz I.F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
9. 9-tetrahydrocannabinol in laboratory rodents. Arch. Int. Pharmacodyn. 196:1972;133-145.
10. Dixon D.M., Traynor J.R. Formation of [Leu5]-enkephalin from dynorphin (1-8) by rat central nervous tissue in vitro. J. Neurochem. 54:1990;1379-1385.
11. Ghosh P., Bhattacharya S.K. Cannabis-induced potentiation of morphine analgesia in rat. Role of brain monoamines Indian J. Med. Res. 70:1979;275-282.
12. Harris L.S., Pierson A.K. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143:1964;141-148.
13. Hollt V. Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26:1986;59-77.
14. Horan P., Tallarida R.J., Haaseth R.C., Matsunaga T.O., Hruby V.J., Porecca F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice. Supra- and subadditivity Life Sci. 50:1992;1535-1541.
15. Jain A.K., Ryan J.R., McMahon F.G., Smith G. Evaluation of intramuscular levonantrodol and placebo in acute postoperative pain. J. Clin. Pharmacol. 21:1981;320S-326S.
16. Lane M., Vogel C.L., Ferguson J., Krasnow S., Saiers J.L., Hamm J., Salva K., Wiernik P.H., Holroyde C.P., Hammill S. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J. Symptom Manage. 6:1991;352-359.
17. Lichtman A.H., Martin B.R. Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J. Pharmacol. Exp. Therap. 258:1991;517-523.
18. Lichtman A.H., Martin B.R. Cannabinoid-induced antinociception is mediated by a spinal alpha-2-noradrenergic mechanism. Brain Res. 559:1991;309-314.
19. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
20. Martin B.R. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci. 36:1985;1523-1530.
21. Mechoulam R. Recent advances in the use of cannabinoids as therapeutic agents. Agurell S., Dewey W., Willitte B. The cannabinoids. Chemical, pharmacologic and therapeutic agents:; 1984;777-793 Academic Press, Inc, New York.
22. Milne G.M., Koe B.K., Johnson M.R. Stereospecific and potent analgesic activity of nantradol - A structurally novel, cannabinoid-related analgetic. NIDA Res. Monogr. 27:1980;84-92.
23. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
24. Narimatsu S., Watanabe K., Yamamoto I., Yoshimura H. Sex differences in the oxidative metabolism of delta 9-tetrahydrocannabinol in the rat. Biochem. Pharmacol. 41:1991;1187-1194.
25. 9-tetrahydrocannabinol. Braude M.C., Szara S. The pharmacology of marihuana. 1976;833-836 Raven Press, New York.
26. Noyes R., Brunk S.F., Avery D.H., Canter A. The analgesic properties of delta-hydrocannabinol and codeine. Clin. Pharacol. Ther. 18:1975;84-89.
27. Pertwee R.G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:1988;189-261.
28. Pugh G., Abood M.E., Welch S.P. Antisense oligonucleotides to the kappa-1 receptor block the antinociceptive effects of delta-9-THC in the spinal cord. Brain Res. 689:1995;157-158.
29. Pugh G., Smith P.B., Dombrowski D.S., Welch S.P. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta-9-THC and morphine in the spinal cord. J. Pharmacol. Exp. Ther. 279:1996;608-616.
30. Raft D., Gregg J., Ghia J., Harris L.H. Effect of intravenous tetrahydrocannabinol on experimental surgical pain. Clin. Pharmacol. Ther. 21:1977;26-36.
31. 3H-leucine enkephalin to a particulate fraction of rat brain. Mol. Pharmacol. 21:1982;538-547.
32. Saxen M.A., Welch S.P., Dewey W.L. The mouse withdrawal assay. A method for determining the effect of calcitonin gene-related peptide on cutaneous heat nociceptive latency time Life Sci. 53:1993;397-405.
33. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
34. Smith P.B., Martin B.R. Spinal mechanisms of delta-9-tetrahydrocannabinol-induced analgesia. Brain Res. 578:1992;8-12.
35. Smith P.B., Welch S.P., Martin B.R. Interactions between delta-9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268:1994;1381-1387.
36. Staquet M., Gantt C., Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin. Pharmacol. Ther. 23:1978;397-401.
37. Sutters K.A., Miaskowski C., Taiwo Y.O., Levine J.D. Analgesic synergy and improved motor function produced by combinations of mu-delta and mu-kappa opioids. Brain Res. 530:1990;290-294.
38. Tallarida R.J., Murray R.B. Manual of pharmacologic calculations with computer programs. 2:1987;Springer Verlag, New York.
39. Tam Y.K. Individual variation in first-pass metabolism. Clin. Pharmacokinet. 25:1993;300-328.
40. 9-THC-DMH. J. Pharmacol. Exp. Ther. 263:1991;1383-1390.
41. Vaught J.L., Takemori A.E. Differential effects of leucine and methionine enkephalin on morphine induced analgesia, acute tolerance and dependence. J. Pharmacol. Exp. Ther. 208:1979;86-90.
42. Wall M.E., Perez-Reyes M. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. J. Clin. Pharmacol. 21:1981;178S-189S.
43. Welch S.P. Modulation of cannabinoid-induced antinociception by nor-binaltorphimine, but not by N,N-diallyl-tyrosine-aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.
44. Welch S.P. Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol. Biochem. Behav. 49:1994;929-934.
45. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262:1992;10-18.
46. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular vs. intrathecal administration to mice. Possible mechanisms for interaction with morphine J. Pharmacol. Exp. Ther. 272:1995;310-321.
47. 9-tetrahydrocannabinol on memory, speech and perception of thermal stimulation. Results with four normal human subjects Prelim. Rep. Compr. Psychiatry. 14:1973;549-556.